NCT02114385View on ClinicalTrials.gov

A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)

PHASE3CompletedINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

March 24, 2014

Primary Completion Date

April 22, 2015

Study Completion Date

April 22, 2015

Conditions
Papilloma Viral Infection
Interventions
BIOLOGICAL

V503

9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection

BIOLOGICAL

GARDASIL

Quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection

Trial Locations (7)

Unknown

Sanofi Pasteur MSD Investigational Site 1002, Ghent

Sanofi Pasteur MSD Investigational Site 1003, Leuven

Sanofi Pasteur MSD Investigational Site 1001, Wilrijk

Sanofi Pasteur MSD Investigational Site 3001, Mainz

Sanofi Pasteur MSD Investigational Site 4001, Amsterdam

Sanofi Pasteur MSD Investigational Site 4003, Amsterdam

Sanofi Pasteur MSD Investigational Site 4002, Nijmegen

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02114385 - A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020) | Biotech Hunter | Biotech Hunter